- Home
- IFRX
IFRX
InflaRx N.V.
as 04-01-2025 4:00pm EST
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
| Founded: | 2007 | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 117.8M | IPO Year: | 2017 |
| Target Price: | $9.00 | AVG Volume (30 days): | 356.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.01 - $2.81 | Next Earning Date: | 03-20-2025 |
| Revenue: | $171,642 | Revenue Growth: | 162.79% |
| Revenue Growth (this year): | 381.73% | Revenue Growth (next year): | 2277.23% |
Latest InflaRx N.V. News
IFRX Breaking Stock News: Dive into IFRX Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
GlobeNewswire
13 days ago
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
GlobeNewswire
a month ago
InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
GlobeNewswire
a month ago
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
GlobeNewswire
a month ago
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
GlobeNewswire
a month ago
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
MT Newswires
2 months ago
Sector Update: Health Care Stocks Flat to Higher Premarket Friday
MT Newswires
2 months ago
InflaRx Slumps Premarket After Pricing $30 Million Offering of Ordinary Shares, Pre-Funded Warrants
Compare IFRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IFRX InflaRx N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.